Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial

2023250 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet

Volume 402, Issue 10405, pp. 859-870

Field-Weighted Citation Impact: 49.60